Europe Cartilage Degeneration Market Analysis and Opportunities by 2027

The Europe cartilage degeneration market is expected to reach US$ 3,365.09 million by 2027 from US$ 2,463.16 million in 2019; it is estimated to grow at a CAGR of 4.1% from 2020 to 2027.

The increasing prevalence of sports injuries and obesity is driving the growth of cartilage degeneration market in the region. However, the high cost of cartilage therapies and lack of reimbursement scenario are the major factors hindering the market growth in Europe.

Degeneration of cartilage can lead to pain and chronic inflammation in joints of the human body. Furthermore, damaged cartilage can potentially influence the quality of a patient’s life. Continuous research and developments are innovating new techniques and methodologies to deal with damaged cartilages. A few of these techniques comprise joint replacement, cell therapies, and chondroplasty.

According to a study published by British Journal of Sports Medicine, an estimated 3.1% of adults in Germany suffer from a sports injury, with an annual injury rate of 5.6%, ranking sports injuries as the second most common type of accident. Further, most common injuries observed among children and teenagers are sprains and strains. Dislocations, distortions, and/or torn ligaments make up 60% of all sports injuries, followed by fractures (18%), contusions, surface wounds, or open wounds (12%). An increasing number of incidents of sports injuries among players and athletes is anticipated to drive the growth of the cartilage degeneration market during the forecast period.

Additionally, European Home and Leisure Accidents Surveillance System (EHLASS), and official German statistics indicate that fatal sports accidents throughout the European Union (EU) and Germany account for only 1% of all fatalities. Also, two-thirds of the injuries are reported in soccer, handball, basketball, and volleyball. The growing number of participants in sports leads to increasing possibilities of sports injuries. Therefore, the rising prevalence of cartilage injuries will eventually accelerate the growth of the cartilage degeneration market in Europe by 2027.

The European economy is severely affected due to the exponential rise in the COVID-19 cases. The Medical Device Regulation (MDR) requires manufacturers to conduct Post Market Clinical Follow-Up (PMCF) studies to demonstrate the continued safety and performance of their devices. This is expected to impact the product launch and ongoing clinical trials of medical devices, thereby hampering the sales and the market growth. Also, disrupted supply chains, extended lockdowns, and canceling of other medical procedures have adversely affected the growth of the cartilage degeneration market in Europe.

Rest of Europe Cartilage Degeneration Market, Revenue and Forecast to 2027 (US$ Mn)

EUROPE CARTILAGE DEGENERATION MARKET SEGMENTATION

By Procedure Type

• Joint Replacement
• Chondroplasty
• Cell-based Cartilage Resurfacing
• Osteochondral Transplant
• Meniscus Transplants
• Others

By Application

• Knee
• Hips
• Other

By End User

• Hospitals and Specialty Clinics
• Ambulatory Surgical Centers
• Academic and Research Institutes

By Country

• Germany
• UK
• France
• Italy
• Spain

Company Profiles

• B. Braun Melsungen AG
• Smith & Nephew
• Stryker Corporation
• CartiHeal, Inc
• Vericel Corporation

Europe Cartilage Degeneration Report Scope